muramidase and Stomatitis

Topics: Adolescent; Adult; Aged; Bacitracin; Cheilitis; Child; Clinical Trials as Topic; Female; Gingivitis; Gingivitis, Necrotizing Ulcerative; Glossitis; Humans; Lichen Planus; Male; Middle Aged; Mouth Diseases; Muramidase; Papain; Salivary Gland Diseases; Stomatitis; Stomatitis, Aphthous; Tooth Extraction

This observational clinical study was composed of two substudies: a non-comparative one (n = 166), testing only lysozyme-based compounds (LBCs), and a comparative substudy (n = 275), testing both LBCs and bicarbonate-based local compounds (BBCs) on the healing of oral mucositis during radio- or chemotherapy. The density of ulcerations has decreased significantly after the treatment with lysozyme in both substudies. The density of ulcerations in the radiotherapy group was lower in patients treated with LBCs compared to patients treated with BBCs (p < 0.001). In the chemotherapy group, reduction of ulceration density was similar with both LBCs and BBCs. The LBCs reduced pain intensity during the intake of solid food and speech more than BBCs in both patient cohorts (p < 0.05). In the radiotherapy cohort, pain intensity when consuming liquid foods was reduced more with LBCs than with BBCs (p < 0.05). No adverse events were recorded. This study demonstrates the advantages of treating oral mucositis during radiotherapy or chemo-therapy with LBCs.

Topics: Antineoplastic Agents; Dermatologic Agents; Female; Humans; Male; Middle Aged; Muramidase; Pain; Radiotherapy; Stomatitis

The objectives of this study were to evaluate the local oral defense mechanisms during the course of leukemia, and to define the correlation between the activity of salivary antibacterial factors and the oral clinical findings.. A total of 44 children with newly diagnosed acute leukemia participated in the study. The control group consisted of 23 healthy children. The examination took place at the time of the diagnosis, and during and at the end of the chemotherapy treatment course. During the collection of resting mixed saliva samples the salivary flow rate was measured. In the saliva's supernatant the following parameters were determined: total protein, peroxidase, myeloperoxidase, lysozyme, lactoferrin, and secretory immunoglobulin A.. The introduction of chemotherapy caused a slight decrease of salivary secretion rate (P < .05), as well as the decrease of S-IgA concentration (P < .01), which remained at the same level after the end of chemotherapy (P < .001). Patients with aplasia had decreased levels of peroxidase (P = .014) and myeloperoxidase (P = .013). Patients with oral mucositis presented with lower myeloperoxidase (P = .026) and peroxidase (P = .003) activity levels as well as the drop of S-IgA (P = .000) concentration compared with subjects with no mucositis.. Antileukemic treatment contributes to the compromise of salivary defense mechanisms, therefore it is reasonable to support pharmacologically the saliva's antibacterial potential of leukemic patients to impede the development of local infection.

Topics: Adolescent; Anti-Infective Agents; Antineoplastic Agents; Antioxidants; Child; Child, Preschool; Female; Humans; Immunoglobulin A, Secretory; Lactoferrin; Leukemia; Male; Mucositis; Muramidase; Opportunistic Infections; Peroxidase; Saliva; Salivary Proteins and Peptides; Secretory Rate; Stomatitis

Melphalan-based autologous stem cell transplant (Mel-ASCT) is a standard therapy for multiple myeloma, but is associated with severe oral mucositis (OM). To identify predictors for severe OM, we studied 381 consecutive newly diagnosed myeloma patients who received Mel-ASCT. Melphalan was given at 200 mg/m2 body surface area (BSA), reduced to 140 mg/m2 for serum creatinine >3 mg/dl. Potential covariates included demographics, pre-transplant serum albumin and renal and liver function tests, and mg/kg melphalan dose received. The BSA dosing resulted in a wide range of melphalan doses given (2.4-6.2 mg/kg). OM developed in 75% of patients and was severe in 21%. Predictors of severe OM in multiple logistic regression analyses were high serum creatinine (odds ratio (OR)=1.581; 95% confidence interval (CI): 1.080-2.313; P=0.018) and high mg/kg melphalan (OR=1.595; 95% CI: 1.065-2.389; P=0.023). An OM prediction model was developed based on these variables. We concluded that BSA dosing of melphalan results in wide variations in the mg/kg dose, and that patients with renal dysfunction who are scheduled to receive a high mg/kg melphalan dose have the greatest risk for severe OM following Mel-ASCT. Pharmacogenomic and pharmacokinetic studies are needed to better understand interpatient variability of melphalan exposure and toxicity.

Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Combinations; Female; Glucose Oxidase; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kidney Diseases; Lactoperoxidase; Male; Melphalan; Middle Aged; Models, Theoretical; Multiple Myeloma; Muramidase; Myeloablative Agonists; Predictive Value of Tests; Regression Analysis; Retrospective Studies; Risk Factors; Severity of Illness Index; Stomatitis; Transplantation Conditioning; Transplantation, Autologous

Topics: Aged; Antibody Formation; Denture, Complete; Humans; Immunoglobulin A, Secretory; Immunoglobulins; Middle Aged; Muramidase; Saliva; Stomatitis; Stomatitis, Denture

Topics: Adult; Aged; Candidiasis, Oral; Female; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Muramidase; Saliva; Stomatitis; Stomatitis, Denture

Topics: Humans; Laparotomy; Muramidase; Postoperative Complications; Saliva; Stomatitis; Time Factors

Topics: Adrenocorticotropic Hormone; Aminobenzoates; Anti-Inflammatory Agents; Dental Pulp Capping; Edema; Enzyme Therapy; Female; Glucocorticoids; Humans; Indomethacin; Inflammation; Male; Mouth Diseases; Muramidase; Nicotinic Acids; Oxyphenbutazone; Postoperative Complications; Pyrazoles; Salicylates; Stomatitis

Topics: Antiviral Agents; Dermatologic Agents; Humans; Mumps; Muramidase; Parotitis; Stomatitis; Virus Diseases

Topics: Antiviral Agents; Micrococcus; Muramidase; Riboflavin; Saliva; Stomatitis

Topics: Antiviral Agents; Epithelial Cells; Humans; Lip; Muramidase; Riboflavin; Saliva; Stomatitis; Vitamin B Deficiency

Topics: Antiviral Agents; Humans; Muramidase; Riboflavin; Saliva; Stomatitis; Vitamin B Deficiency